The present study is designed to evaluate the combined efficacy of Platelet Rich Fibrin (PRF) and 1.2% Rosuvastatin (RSV) with open flap debridement (OFD) in treatment of intrabony defects in chronic periodontitis patients
ABSTRACT Background: Regenerative periodontal therapy encompasses the use of various bioactive agents that are not only inflammo-modulatory but also osteoclast-inhibitory or rather, osteostimulative. The hypolipidaemic Statin group of drugs, particularly Rosuvastatin (RSV), are known to be associated with alveolar bone formation and periodontal improvements. Platelet analogues like Platelet rich fibrin (PRF), being rich sources of growth factors, have also come into widespread periodontal regenerative use. The aim of the study is to evaluate and compare the efficacy of open-flap debridement (OFD) with or without PRF or PRF + 1.2% RSV gel in the treatment of intrabony defects (IBDs) in chronic periodontitis (CP) patients. Methods: Ninety individuals with a total of 90 IBDs were randomly assigned to one of the 3 treatment groups: 1) OFD alone, 2) OFD + PRF and 3) OFD + PRF + 1.2% RSV gel placement. Plaque index (PI), modified sulcus bleeding index (mSBI), probing depth (PD), clinical attachment (CA) level and IBD depth were recorded at baseline and at 9 months post-operatively.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
90
Oral prophylaxis followed by OFD for treating bone defect
Oral prophylaxis followed by OFD with PRF placement into the bone defect
Oral prophylaxis followed by OFD with PRF and 1.2% Rosuvastatin placement into the bone defect
Government Dental College and Research Institute
Bangalore, Karnataka, India
defect depth reduction (%)
assessed in percentage
Time frame: Change from baseline to 9 months
probing depth (mm)
measured in mm
Time frame: Change from baseline to 9 months
clinical attachment level (mm)
measured in mm
Time frame: Change from baseline to 9 months
modified sulcus bleeding index
scale from 0-3
Time frame: Change from baseline to 9 months
plaque index
scale from 0-3
Time frame: Change from baseline to 9 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.